Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis.
Journal: Dermatology and therapy
Published: March 02, 2026
Dupilumab normalizes the eosinophilic esophagitis disease transcriptome.
Journal: The Journal of allergy and clinical immunology
Published: August 08, 2025
Sarilumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Dose-Finding and 1-Year Analysis of a Phase 2b, Open-Label, Multicenter Study.
Journal: Arthritis care & research
Published: January 22, 2025
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Journal: Frontiers in immunology
Published: July 17, 2024
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Journal: The New England journal of medicine
Published: May 20, 2024
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.
Journal: Allergy
Published: December 13, 2023
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Journal: The New England journal of medicine
Published: October 04, 2023
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
Journal: Journal of the American Academy of Dermatology
Published: October 03, 2023
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
Journal: The Journal of allergy and clinical immunology
Published: October 02, 2023
Last Updated: 09/26/2026